22 / 33
WHEN to test?
Initial diagnosis preferable
•
PRO
•
Access to pathology
•
Biomarker of response to platinum-based chemotherapy
•
Prognostic factor
•
Genetic counseling
•
Likely PARPi will be approved in front-line setting
•
CON: “
Evidence supporting temporal heterogeneity in OC”